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Abstract
Background: In Myanmar, approximately half of all neonatal hospital admissions are for hyperbilirubinaemia, and
tertiary facilities report high rates of Exchange Transfusion (ET). The aim of this study was to evaluate the
effectiveness of the pilot program in reducing ET, separately of inborn and outborn neonates.
Methods: The study was conducted in the Neonatal Care Units of four national tertiary hospitals: two exclusively
treating inborn neonates, and two solely for outborn neonates. Prior to intervention, no high intensity phototherapy
was available in these units. Intervention in late November 2011 comprised, for each hospital, provision of two high
intensity LED phototherapy machines, a photo radiometer, and training of personnel. Hospital-specific data were
assessed as Relative Risk (RR) ratios comparing ET rates pre- and post-intervention, and individual hospital results were
pooled when appropriate.
Results: In 2011, there were 118 ETs among inborn neonates and 140 ETs among outborn neonates. The ET rate was
unchanged at Inborn Hospital A (RR = 1.07; 95 % CI: 0.80–1.43; p = 0.67), and reduced by 69 % at Inborn Hospital B
(RR = 0.31; 95 % CI: 0.17–0.57; p < 0.0001). For outborn neonates, the pooled estimate indicated that ET rates
reduced by 33 % post-intervention (RRMH = 0.67; 95 % CI: 0.52–0.87; p = 0.002); heterogeneity was not a problem.
Conclusion: Together with a photoradiometer and education, intensive phototherapy can significantly reduce the ET
rate. Inborn Hospital A had four times as many admissions for jaundice as Inborn Hospital B, and did not reduce ET
until it received additional high intensity machines. The results highlight the importance of providing enough intensive
phototherapy units to treat all neonates requiring high intensity treatment for a full course.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12615001171505, 2 November 2015.
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Background
Neonatal jaundice is found in about 60 % of term and
80 % of preterm neonates in the first week of life [1],
because neonates produce bilirubin at unusually high
rates, and are inefficient at metabolising and excreting
it [2]. This ‘physiological jaundice’ usually resolves
spontaneously, and can be differentiated from a number
of pathological conditions (e.g., Rh (D) isoimmunisation,
ABO incompatibility) which result in extreme hyperbiliru-
binaemia [3]. Blood exchange transfusion (ET) is a com-
mon intervention to treat extreme hyperbilirubinaemia
with the goal of preventing bilirubin encephalopathy and
death [4], rapidly removing about 50 % of the circulating
bilirubin [5]. While effective, ET is associated with a range
of procedure-related risks of mortality and morbidity [4].
We are not aware of any estimates of national ET
rates, but hospital-based studies provide some guide. A
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Greek study reported the ET rates in an Athens mater-
nity hospital during 1957–1961 at 435 ET per 100,000
live births and, after the introduction of routine photo-
therapy, a much lower rate of 50 ET per 100,000 live
births in a separate Athens maternity hospital in 1980–
1992 [6]. Similarly, the ET rate among inborn neonates
at a single hospital in the USA during the period 1986–
2006 averaged an estimated 74 neonates per 100,000 live
births, with a statistically significant reduction in ex-
change transfusion incidence over time [7]. The re-
duction in ET in industrialised countries can be
attributed to a number of factors, including screening
for ABO and Rh blood types and obstetric or neo-
natal treatment [7], early neonatal screening for jaun-
dice, and the adoption of phototherapy as a means of
preventing exchange transfusion [8].
In Myanmar, the National Hospital Statistics Report
for 2011 reveals that admissions relating to neonatal
jaundice are responsible for 46 % of all hospital admis-
sions for conditions originating in the perinatal period
[9]. While we are not aware of national data on ET rates
in Myanmar, internal data from two tertiary maternity
hospitals (the Central Women’s Hospitals of Yangon and
Mandalay; ‘Inborn Hospitals A and B’) and two tertiary
paediatric hospitals (Yangon Children’s Hospital and
Mandalay 300-bedded Children’s Hospital; ‘Outborn
Hospitals A and B’) showed unexpectedly high rates of
ET. A pilot program was implemented at these four
hospitals, to improve treatment of neonates admitted to
the Neonatal Care Units (NCUs).
The aim of this study was to evaluate the effectiveness




Inborn Hospitals A and B are both national tertiary ob-
stetric referral hospitals that only admit inborn neonates,
while Outborn Hospitals A and B are both tertiary
paediatric referral hospitals that only admit outborn neo-
nates. Prior to 2014, all four hospitals had NCUs which
provided care at American Academy of Pediatrics [AAP]
Level 2B [10].
All hospitals used conventional blue-light photother-
apy machines (Philips 20 W/52 blue tubes or Yondon
20 W YD-FL-20W) at the time of intervention. Despite
the fact that hospital staff attempted to replace lights
regularly, the lack of a photo radiometer meant that cli-
nicians were frequently uncertain as to the quality of
treatment they were providing. The irradiance of some
of the conventional phototherapy machines was measured
using a photo radiometer (BLMv7; Medical Technology
Transfer and Services [MTTS], Hanoi, Vietnam) in June
2011. Results are shown in Table 1 separately for single
and double-sided machines; the irradiance and was in the
range 5–23 μW/nm/cm2.
Intervention
In November 2011, each hospital participated in an
intervention funded and implemented by the Breath of
Life (BOL) program of Thrive Networks, an inter-
national non-governmental organization. The interven-
tion comprised provision of NCU equipment, including
two LED phototherapy machines (MTTS PTV3000) and
a photo radiometer (MTTS BLMv7), and training from
one of the authors (DT) covering a variety of clinical
subjects including management of neonatal hyperbiliru-
binaemia and phototherapy. The MTTS PTV3000 pro-
vides phototherapy from above, using Philips ‘Luxeon
Rebel Royal Blue’ LED bulbs with a peak wavelength of
455 nm, calibrated at shipping to a maximum irradiance
of 40 μW/nm/cm2 as measured at 40 cm. Calibration
was done using the MTTS BLMv7, which has a sensor
element with a half power response band from 420 to
505 nm (TCS3404CS, Taos Inc., Austria) [11] and a filter
with a half power response band from 441 to 466 nm
[#071 ‘Tokyo Blue’, Filters Op Maat, Netherlands] [12].
The Philips LED bulbs have an expected life (70 %
lumen maintenance) of 50,000 h [13].
Training encouraged use of the AAP 2004 Guidelines
for management of hyperbilirubinaemia in neonates
born at 35 weeks gestation and above [14]; for neonates
born <35 weeks gestation, training promoted use of the
phototherapy treatment and exchange transfusion
thresholds recommended by the UK National Institute
for Clinical Excellence [1]. These were the guidelines
already in use at the Central Women’s Hospital, Yangon,
which is the hospital responsible for setting policy on fa-
cility based neonatal care in Myanmar. Hospital staff
Table 1 Irradiance of conventional blue light phototherapy









Inborn A Single 6 6 12.0 [8–23]
Double - above 2 2 15.0 [10–20]
Double - below 15.0 [10–20]
Inborn B Single 7 7 7.0 [5–11]
Double - above 2 2 11.0 [5–17]
Double - below 12.5 [8–17]
Outborn A Single 9 3 20.0 [11–23]
Double - above 1 1 10.0 [n/a]
Double - below 10.0 [n/a]
Outborn B Single 10 4 11.0 [7–13]
Double - above 3 0 n/a
Double - below
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attended a 4 h meeting to provide training in manage-
ment of hyperbilirubinaemia and use of the equipment,
and to establish a register to record data on neonates
treated on the LED phototherapy machines.
In November and December 2012, additional MTTS
PTV3000 LED machines were donated to each of the
hospitals; three each to Inborn Hospital A and Outborn
Hospital A, and one each to Inborn Hospital B and
Outborn Hospital B.
Data sources for comparing pre- and post-intervention
periods
For the purposes of evaluation we defined the pre-
intervention period as calendar 2011 and the post-
intervention period as calendar 2012. While not pre-
cisely aligned with the date of intervention (late
November 2011), the misclassification was considered
minor. This definition permitted the use of NCU Annual
Reports as the main data sources for the evaluation in
three of the four hospitals. The Annual Reports provided
information on the number of: live births (inborn); NCU
admissions for any reason; NCU admissions specifically
for jaundice or, at Inborn Hospital A where admission for
jaundice was not recorded, NCU admissions treated with
phototherapy; and ETs.
The Annual Reports at Outborn Hospital A did not
contain the relevant data, so de-identified data were
retrospectively collected from the NCU Admission
Register (total admissions and admissions for jaundice)
and the ET Register (number of ETs); as the available
2011 ET Register only commenced in mid-June 2011
(the previous register was not locatable), the pre-
intervention period for this hospital was defined as July–
December 2011, and the post-intervention period as
July–December 2012.
Data source for information on neonates treated on LED
in the post-intervention period
To assist with understanding the intervention, all four
hospitals agreed to collect a limited amount of informa-
tion on each neonate treated, during project implemen-
tation. An LED Treatment Register was established,
including: age at admission (days); Total Serum Bilirubin
(TSB) at admission; duration of LED phototherapy treat-
ment in days (date of end of treatment – date at start);
and TSB prior to exchange transfusion. The LED Treat-
ment Register data was only available following interven-
tion, and for different durations at each hospital, ranging
from 12 to 20 months; at three hospitals reporting was
continuous, stopping at different dates, but in the fourth
(Outborn Hospital A) there were gaps in reporting.
TSB readings at the four facilities could be processed
in a variety of locations: the NCU; the hospital labora-
tory; or an external laboratory. In three of the four
hospitals, the vast majority of tests were performed on
the NCU bilirubin meter, while in the fourth (Outborn
Hospital B) most readings were performed in the hos-
pital laboratory. At one of the hospitals (Outborn Hos-
pital A), the NCU bilirubin reader had a maximum
reading of 30 mg/dL (513 μmol/L); no other Bilirubin
analyser had a maximum reading.
Ethical approval
Retrospective ethics clearance was sought and re-
ceived from the Ethical Committee on Medical Research
Involving Human Subjects, Department of Health,
Myanmar (approval #14/2014), before any publication. As
the study was an evaluation comparing outcomes before
and after routine implementation of an evidence-based
facility-level intervention, approved retrospectively, the
Ethics Committee did not require informed parental
consent.
Analysis
Relative Risk ratios (RRs) were calculated by comparing
pre- and post-intervention ET rates. Inborn and Out-
born hospitals were analysed separately and the two hos-
pitals in each group were treated as separate strata.
Heterogeneity was assessed by examining Cochran’s Q
and the I2 statistic [15], with an I2 value of >40 % taken
to indicate important levels of heterogeneity. If im-
portant heterogeneity was identified, hospital RRs
were reported individually and sources of heterogen-
eity explored. If heterogeneity was not identified,
hospital-specific RRs were pooled using the Mantel-
Haenszel method, assuming a fixed-effects model. As-
sessments of heterogeneity and pooling of data, where
appropriate, were performed in RevMan 5.3 [16].
Results
Pre- and post-intervention data
Table 2 shows key characteristics of the two mater-
nity hospitals, and Table 3 shows key characteristics
of the two paediatric hospitals.
In 2011, there were 118 ETs among inborn neo-
nates at the two maternity hospitals, decreasing to 94
ETs in 2012 (Table 4). At Inborn Hospital A, the ET
rate among neonates admitted for jaundice was
10.0 % pre-intervention and 10.7 % post-intervention
(RR = 1.07; 95 % CI: 0.80–1.43; p = 0.68). At hospital
B, by contrast, the intervention rate reduced dramat-
ically from 17.8 % pre-intervention to 5.5 % post-
intervention, resulting in a 69 % relative reduction in ET
rates (RR = 0.31; 95 % CI: 0.17–0.57; p < 0.0001). The pres-
ence of substantial heterogeneity (I2 = 92 %) prevented the
pooling of these data.
The NCU Director of Inborn Hospital A revealed that
during 2012 jaundiced patients were being removed
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from the LED machines before treatment was complete,
to try and offer the benefit of the higher irradiance to as
many neonates as possible; we were informed that this
practice stopped after an additional three LED machines
were provided in November 2012. We therefore decided to
undertake a post hoc analysis, comparing 2013 ET data with
the 2011 (baseline) data, to explore the possible impact of
additional machines. The results or the post hoc analysis,
are shown in Table 5: the 2013 ET rate at Inborn Hospital
A reduced to 3.2 %, leading to a 68 % relative reduction in
ET rates (RR2013 vs 2011 = 0.32; 95 % CI: 0.21–0.48; p <
0.0001), while the 2013 ET rate at Inborn Hospital B was
7.8 % resulting in a 56 % relative reduction (RR2013 vs 2011 =
0.44; 95 % CI: 0.25–0.77; p < 0.0001). As heterogeneity was
no longer observed, a pooled result was calculated, showing
a reduction of ET by 64 % among inborn neonates (RRMH
2013 vs 2011 = 0.36; 95 % CI: 0.26–0.49; p < 0.0001). Relevant
to this analysis, we note that Inborn Hospital A also
received 7 Lullaby LED Phototherapy Units [GE Health-
care, Maryland, USA] [17] in November 2013, overlapping
the end of the second post-intervention period.
Among outborn neonates, there were 140 ETs in 2011
and 47 in 2012. As shown in Table 6 the ET rate at Out-
born Hospital A reduced from 31.7 % of admissions for
jaundice in 2011 to 19.2 % in 2012 (RR = 0.61; 95 % CI:
0.42–0.87; p = 0.008). At Outborn Hospital B, the ET
rate reduced from 29.2 % in 2011 to 21.5 % in 2012 (RR
= 0.74; 95 % CI: 0.51–1.07; p = 0.10). As there was lim-
ited heterogeneity the pooled result was calculated, lead-
ing to an overall estimate of a 33 % relative reduction in
ET rates across the two paediatric hospitals (RRMH =
0.67; 95 % CI: 0.52–0.87; p = 0.002).
Post-intervention data on LED treated neonates
Selected characteristics of neonates treated on the LED
phototherapy machines are shown at Table 7 Conventional
Table 2 Characteristics of two tertiary Myanmar maternity hospitals, in 2011 and 2012
Inborn Hospital A Inborn Hospital B
2011 2012 2011 2012
Live births 7509 8720 5696 5369
NCU admissions 1102 1259 1678 1644
NCU admission rate 14.7 % 14.4 % 29.5 % 30.6 %
Admissions for Jaundicea 747 832 242 220
% of NCU admissions 67.8 % 66.1 % 14.4 % 13.4 %
Estimated number of phototherapy machinesb Conventional – single sided 6 7
Conventional – double sided 2 2
LED From November 2011: 2 From November 2011: 2
From November 2012: 5 From December 2012: 3
Date of intervention 23 November, 2011 21 November, 2011
aAt Inborn Hospital A this was actually infants treated with phototherapy, rather than being admissions for jaundice
bNumber of conventional machines are as recorded as hospital visit in June 2011 – this number was not subsequently monitored, but is not believed to have
changed markedly in 2012
Table 3 Characteristics of two tertiary Myanmar paediatric hospitals, in 2011 and 2012
Outborn Hospital A Outborn Hospital B
2011 2012 2011 2012
NCU admissions 1363 1408 765 492
Admissions for Jaundice 363 366 281 135
% of NCU admissions 26.6 % 26.0 % 36.7 % 27.4 %
Estimated number of phototherapy machinesa Conventional – single sided 9 10
Conventional – double sided 1 3
LED From November 2011: 2 From November 2011: 2
From November 2012: 5 From December 2012: 3
Date of intervention 23 November, 2011 21 November, 2011
aNumber of conventional machines are as recorded as hospital visit in June 2011 – this number was not subsequently monitored, but is not believed to have
changed markedly in 2012
Arnolda et al. BMC Pediatrics  (2015) 15:216 Page 4 of 10
blue-light phototherapy machines were also used during
this period, but clinicians indicated that the LED machines
were preferentially allocated to neonates with higher TSB.
Median age at admission was 2 days for neonates admit-
ted to the inborn NCUs compared to 3 days in the two
outborn NCUs. While the median TSB at admission was
slightly lower for the inborn neonates (301 and 249 μmol/
L) than the outborn neonates (325 and 311 μmol/L), there
is a marked difference in the distributions. The proportion
of neonates admitted with extreme hyperbilirubinemia
(TSB > 427 μmol/L) was 3.7–4.3 % of inborn neonates, in
comparison to 28–32 % among outborn neonates.
Of those with extreme hyperbilirubinaemia, the propor-
tion who had an ET varied enormously: 92 % and 45 % in
the two maternity hospitals, and 67 % and 39 % in the two
paediatric hospitals. The median age at admission of neo-
nates with extreme hyperbilirubinaemia was 2–3 days for
the two maternity hospitals, and 3–4 days for the two
paediatric hospitals, and was not markedly later than for
neonates without extreme hyperbilirubinaemia at admis-
sion (median of 2 days at both maternity hospitals, and
3 days at both paediatric hospitals). The only statistically
significant difference was in Outborn Hospital A, where ne-
onates with extreme hyperbilirubinaemia were admitted at
a median of 4 days compared to 3 days for neonates with-
out extreme hyperbilirubinaemia (p = 0.03 by Kruskal-
Wallis test).
The duration of LED phototherapy was a median of
1 day at Inborn Hospital A and Outborn Hospital A, and
2 days at the Inborn Hospital B and Outborn Hospital B.
TSB at ET was available for a subset of neonates that re-
ceived LED phototherapy and went on to receive a trans-
fusion. Median TSB at ET was noticeably lower among
the inborn neonates having ETs (393 and 405 μmol/L)
than the outborn neonates (500 and 474 μmol/L).
Discussion
While ET is valuable for preventing bilirubin encephalop-
athy, the procedure is itself associated with mortality and
morbidity and should be avoided whenever possible. In
high resource settings, estimates of procedure related
mortality from the 1950s to the 1970s, before it was estab-
lished that phototherapy was effective at reducing ET,
ranged from 3.7/1000 to 32.0/1000 ETs [18–24]. In
low resource settings, where ET is still required at
least in part due to unavailability of intensive photo-
therapy, results have been reported ranging from 0 to
182 deaths/1000 ETs [25–30]. The commonest mor-
bidities associated with ET are thrombocytopenia and
hypocalcaemia in both high [7, 31] and low resource
settings [4, 25–28].
Phototherapy has been proven by randomised trial to
markedly reduce the need for ET in high resource set-
tings [8], so the current study merely seeks to quantify
the reduction possible in a low resource setting. The
current study confirms that simple provision of LED
phototherapy, a photo radiometer, and provision of stan-
dardised training in use of existing guidelines, can result
in a 33 % reduction in ET among outborn neonates, and
a reduction of ET of 68 % at one hospital treating inborn
neonates, and no reduction at the other.
In exploring this heterogeneity in the inborn hospital
results, clinicians stated that patients were being re-
moved from the LED phototherapy machines early in an
attempt to share the high intensity treatment among as
many patients as possible, as there were too many
Table 4 Relative risk of ET in two tertiary Myanmar maternity hospitals, in 2011 and 2012
Hospital Period Admissions for jaundice ET % ET RR [95 % CI] RRMH [95 % CI]
Inborn Hospital A
2011 747 75 10.0 %
1.07 [0.80–1.43]
nca
2012 832 82 10.7 %
Inborn Hospital B
2011 242 43 17.8 %
0.31 [0.17–0.57]
2012 220 12 5.5 %
RR Relative Risk ratio, RRMH Mantel-Haenszel pooled RR
aRRMH not calculated due to extreme heterogeneity (I
2 = 92 %)
Table 5 Relative risk of ET in two tertiary Myanmar maternity hospitals, with 2013 as post-intervention period
Hospital Period Admissions for jaundice ET % ET RR [95 % CI] RRMH [95 % CI]
Inborn Hospital A
2011 747 75 10.0 %
0.32 [0.21–0.48]
0.36 [0.26–0.49]
2013 968 31 3.2 %
Inborn Hospital B
2011 242 43 17.8 %
0.44 [0.25–0.77]
2013 192 15 7.8 %
RR Relative Risk ratio, RRMH Mantel-Haenszel pooled RR
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patients to be treated. A supplementary, post hoc, ana-
lysis was therefore defined comparing a period after add-
itional LED machines had been provided to the inborn
hospitals (2013); there was no heterogeneity in this ana-
lysis, and it suggested a reduction of 64 % among inborn
neonates across the two hospitals. Caution must be
taken in interpreting this result, because the time pe-
riods was defined post hoc, but the absence of hetero-
geneity in the results across the two inborn NCUs, and
its conformance with randomised trial results, suggest
that it is plausible. Nevertheless, it is also plausible that
other relevant factors, the specifics of which we are un-
aware, also changed.
Differential impact among inborn vs outborn neonates
The estimated relative reduction in ET at one maternity
hospital in the formal analysis, and both in the supple-
mentary period, was twice that found in paediatric
hospitals. Data from the LED Treatment Registers show
that that the median TSB at admission is roughly similar
for both inborn and outborn neonates, but the distribu-
tions are strikingly different, with almost a third of
outborn neonates admitted with extreme hyperbilirubi-
naemia in comparison to just 4 % of inborn neonates.
Late admission of outborn neonates has been reported
in many case series. For example, one Nigerian case
series found that 25 of 28 neonates admitted with Acute
Bilirubin Encephalopathy (ABE) were outborn [32],
another found that all six neonates with kernicterus
were outborn [33], and a third reported that 26 of 27
cases of ABE were outborn – the sole inborn neonate to
develop ABE followed parental refusal of ET [34]. When
neonates are admitted with signs of ABE, prompt ET is
recommended [14].
The results in the paediatric hospitals demonstrate
that the simple interventions reported here can have a
Table 6 Relative risk of ET in two tertiary Myanmar paediatric hospitals, in 2011 and 2012
Hospital Period Admissions for jaundice ET % ET RR [95 % CI] RRMH [95 % CI]
Outborn Hospital A
2011a 183 58 31.7 %
0.61 [0.42–0.87]
0.67 [0.52–0.87]
2012a 182 35 19.2 %
Outborn Hospital B
2011 281 82 29.2 %
0.74 [0.51–1.07]
2012 135 12 21.5 %
RR Relative Risk ratio, RRMH Mantel-Haenszel pooled RR
aOutborn Hospital A data restricted to the 6 months July–December of these years, as ET Register unavailable prior to July 2011
Table 7 Characteristics of neonates treated for jaundice with LED machines post-intervention
Inborn Outborn
Hospital A Hospital B Hospital A Hospital B
Months reporteda 13 19 12 20
Neonates treated on LED 433 266 339 251
Infants treated/monthaMedian [IQR] 32 (25–49) 12 (10–17) 30 (19.5–34.5) 10.5 (8.5–15)
Age at admission (days)b: Median [IQR] 2.0 [2.0–4.0] 2.0 [1.0–3.0] 3.0 [2.0–5.0] 3.0 [2.0–5.0]
TSB at admissionc (μmol/L): Median [IQR] 301 [255–347] 249 [211–280] 325 [234–473] 311 [224–445]
Admitted with EHc: n (%) 12 [2.8 %] 11 [4.3 %] 105 [31.6 %] 59 [26.8 %]
Of those with EH, number given ET: n (%) 11 [91.7 %] 5 [45.5 %] 70 [66.7 %] 23 [39.0 %]
Age at admission of infants with EH (days): Median [IQR] 3.0 [2.0–4.5] 2.0 [2.0–4.0] 4.0 [2.0–5.0] 3.0 [2.0–4.0]
Age at admission of infants without EH (days): Median [IQR] 2.0 [2.0–4.0] 2.0 [1.0–3.0] 3.0 [2.0–5.0] 3.0 [2.0–5.0]
Duration of phototherapy (days)d: Median [IQR] 1.0 [1.0–1.0] 2.0 [1.0–2.0] 1.0 [1.0–2.0] 2.0 [1.0–2.0]
TSB at ETe (μmol/L): Median [IQR] 393 [335–431] 405 [362–456] 500 [475–513] 474 [416–539]
ET Exchange Transfusion, EH Extreme Hyperbilirubinaemia (TSB >428 μmol/L), IQR Interquartile range
aOutborn Hospital A reported 12 months of data, spread over 20 months from late November 2011 to June 2013, due to staffing interruptions. The other three
hospitals reported data for consecutive month. Data at Inborn Hospital A were partial for the first and last of 14 reporting months, leading to an estimated 13
reporting months; the median and IQR exclude the first and last month
bAge at admission was missing for one record at Inborn Hospital A and four records at Inborn Hospital B
cTSB at admissions was missing for eight records at Inborn Hospital B, seven at Outborn Hospital A, and 31 at Outborn Hospital B
dDuration of phototherapy was missing for 1 neonate at Inborn Hospital A, 2 at Inborn Hospital B, 84 at Outborn Hospital A and 22 at Outborn Hospital B
eTSB at ET was missing for 5 of 64 transfused neonates at Inborn Hospital A, 5 of 18 transfused neonates at Inborn Hospital B, 42 of 88 transfused neonates at
Outborn Hospital A, and 12 of 38 transfused neonates at Outborn Hospital B; note that most readings at Outborn Hospital A were performed on equipment with
a maximum possible reading of 513 μmol/L
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positive impact, but the extent of that impact may be
limited by the ‘late’ presentation of many outborn neo-
nates. In only one of the four hospitals does the data
show that neonates presenting with extreme hyperbiliru-
binaemia at admission were older than neonates present-
ing with lower levels of hyperbilirubinaemia; thus ‘late
presentation’ must be defined in terms of the severity of
illness at the time of hospital presentation, rather than
age of the neonate in days. This can only be addressed
by additional interventions to ensure that parents are
educated to identify rapidly developing jaundice, and
that neonates are regularly and routinely assessed and
promptly referred for treatment when appropriate. It is
estimated that 36 % of births in Myanmar deliver in
facilities [35]; as a substantial proportion of the facility-
born neonates are promptly discharged home, education
of parents and community-based intervention represents
a major undertaking.
Finally, it should be noted that neither maternity hos-
pital NCU accepted inborn neonates back into the nursery
after they were discharged; if inborn neonates required
treatment for jaundice after discharge from the hospital,
they had to be admitted to a separate hospital as an out-
born admission. Thus any ETs avoided by inborn neonates
in this study were ETs during the birth admission. This
policy was unchanged between the two study periods and
does not therefore alter our conclusions about the poten-
tial impact of the intervention on ET rates.
Which intervention elements were important?
The current study was implemented as operational re-
search, exploiting readily available or relatively easily
collected data to evaluate routine roll-out of an
evidence-based intervention. As a result, we are unable
to comment formally about which element(s) of inter-
vention are most important, but can only explore the
evidence. There are three elements of intervention:
provision of LED phototherapy machines; provision of a
photo radiometer; and provision of training using stand-
ard guidelines. We will consider the potential contribu-
tion of each of the elements individually but, as noted
below, we believe that all three elements are essential
components of any intervention to reduce ET.
Role of LED Phototherapy machines
Prior to the provision of LED phototherapy, none of the
phototherapy machines in use at the four pilot hospitals
was providing ‘intensive phototherapy’ (>30 μW/nm/cm2)
as defined in the 2004 AAP Guidelines [14]. The
provision of LED machines delivering irradiance of
40 μW/nm/cm2 represented an increase of irradiance
by a factor of 2–5 times that previously available on
the conventional blue light machines used at the four
hospitals. This increase in irradiance is to some
extent offset by the increase in surface area exposed
by the use of double-sided phototherapy machines, at
least one of which was available in each of the four
NCUs.
Two LED phototherapy machines were provided to
each of the four hospitals. This number of machines was
adequate to facilitate reduction in ET in the three
hospitals with fewer admissions for jaundice (135–366
admissions for jaundice in the post-intervention period;
one LED machine per 68–183 jaundiced neonates), but
inadequate for a hospital with a high volume of jaun-
diced neonates (832 treated neonates; one LED machine
per 416 treated). While we would have anticipated par-
tial reduction in ET rates at this hospital, no reduction
was observed, and we interpreted this as due to the early
cessation of treatment to permit more babies to be
treated with LED. When the number of LED machines
was increased to 5 (968/5 = 194 treated neonates per
LED machine at Hospital), the ET rates reduced sharply;
this suggests that one LED machine is required per 150–
200 admissions for jaundice.
Role of photo radiometer
None of the four hospitals had a photo radiometer prior
to the intervention, and clinicians did not therefore
know the irradiance being provided by each machine. In
addition, very few of the conventional phototherapy ma-
chines in use prior to the intervention had counters
which recorded cumulative hours of use, to facilitate
timely bulb replacement, in line with manufacturers’
specifications (usually 1500 or 2000 h of use). In the
absence of counters, staff can only know when to change
the blue light tubes if they carefully log the number of
hours of use of each machine, to ensure that bulbs are
changed at the appropriate time.
In Myanmar and elsewhere, the BOL program has
noted that simple provision of a photo radiometer often
leads to rapid improvement in the average irradiance of
the conventional machines (due to timely replacement
of tubes) and to triaging of the neonates with the highest
TSB to the machine with the highest irradiance. We did
not systematically assess whether this was the case be-
fore and after the intervention in the current study, so
we cannot confirm, using objective measures, whether
this occurred in any or all of the pilot hospitals, or con-
jecture as to whether it contributed to the observed re-
ductions in ET rates. Clinicians do however confirm
these practices occurred.
Role of agreement to adopt uniform guidelines
It was agreed during the intervention that the AAP
(≥35 weeks) and NICE (<35 weeks) thresholds for man-
agement would be adopted to promote uniformity of
practice, in line with the practice at the Central
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Women’s Hospital, Yangon. During the initial hospital
visits in Myanmar, BOL staff and volunteers noted that
hospitals were using different thresholds for photother-
apy and ET, and were often performing ET below the
recommended thresholds. In discussion with clinicians it
became apparent that the lack of efficacious photother-
apy encourages clinicians to make conservative decisions
and perform ET. For example, if there is little reason to
trust the efficacy of the available phototherapy machines,
it can make sense to do an ET as a threshold is
approached, while the blood bank services are available,
rather than waiting a few hours until the threshold is
inevitably reached and recalling staff to the hospital
premises.
When considered in this context, the provision of ef-
fective phototherapy facilitates compliance with guide-
lines. It is plausible that compliance will increase over
time as clinicians adjust to a new clinical reality, where
rapidly increasing TSB can be treated without ET.
Limitations
There are a number of limitations in the current study.
Some limitations relate to the fact that this study was
implemented as unfunded operational research, reliant
on data collected by hospital staff while performing their
clinical and administrative roles. BOL did not employ
in-country staff with a primary role of supporting hospi-
tals with data-collection until late 2012. A number of
other specific limitations are discussed below.
First, pre-intervention evaluation data was collected
according to local convention rather than external defin-
ition, so it was considered inappropriate to impose an
external definition that applied only to the post-
intervention period. While ET for hyperbilirubinaemia
(the numerator) is straightforward, there was important
variation in the definition of the number of jaundiced
neonates (the denominator). At Inborn Hospital A, the
Annual Report reported the total number of neonates
receiving phototherapy regardless of the reason for
admission; at other hospitals, the number of admis-
sions for jaundice was based on a review of the NCU
Admission Register. To our knowledge, the denominator
definitions did not change markedly in the pre- and post-
intervention periods so, while the ET rates of the four
hospitals may not be directly comparable, the presented
relative risk estimates are believed to be unbiased.
Second, when the NCU Annual Report at Outborn
Hospital A was found to be inaccurate in the recorded
number of ETs for 2011, a retrospective review of the
Admission and ET Registers was undertaken. The rela-
tive risk was calculated by comparing the ET rate for the
6 months July–December 2011 as the pre-intervention
period and the same 6 months of 2012 as the post-
intervention period. Full-year data for 2011 could not be
collected as the available ET Register was initiated in
June 2011. In this hospital, as in the other three pilot
hospitals, the intervention took place in late November
2011, but data for late November and all December
2011 were included as part of the pre-intervention
period. We consider this to be an appropriate designa-
tion as we consider November and December 2011 to
be a ‘wash-in’ period, during which new treatment pro-
tocols were rolled out in the NCUs. Nevertheless, the
fact of having LED phototherapy during this 5 week-
period has the effect of making the pre- and post-
intervention periods more similar, potentially reducing
the size of the estimated relative risks reported here.
Third, Outborn Hospital B saw a one third reduction
in total admissions and halving of the number of neo-
nates admitted for phototherapy. This occurred because
a larger, better-resourced paediatric hospital opened in
the same catchment during the post-intervention period.
It is plausible that the reduction of admissions reflected
the self-referral of sicker neonates to the new hospital. If
so, the average acuity of jaundiced patients in the post-
intervention period may be lower than in the pre-
intervention period, but we lack individual patient data
for the two periods which could support or refute this
hypothesis. Comparing the two paediatric hospitals in-
cluded in this study, however, shows that they had simi-
lar results (ET rates reduced from roughly 30 % pre- to
20 % post-intervention), and patient profiles.
Fourth, the LED Treatment Register data presented in
this report does not represent the entire cohort of
neonates receiving phototherapy during the post-
intervention period. No data was collected on neonates
treated exclusively with conventional phototherapy. Cli-
nicians indicate that the subset of neonates reported
here are likely to be the neonates with higher TSB
values, or who were otherwise considered to be at higher
risk. We do not believe this impacts our interpretations
in any significant way.
Fifth, and finally, we note that for simplicity of data
collection the LED Treatment Register recorded date at
start and end of treatment and calculated duration of
treatment in ‘days’ by subtracting start date from end
date; clearly, it would have been more accurate to count
hours, but this was not done as it would have increased
the reporting load on clinicians.
Conclusions
We report on a simple intervention at four hospitals
comprising the provision, to each hospital, of two LED
phototherapy machines to improve the irradiance pro-
vided for treatment of jaundice, one photo radiometer to
allow hospitals to triage neonates to the most effective
conventional phototherapy machines and to allow them
to ensure high output from conventional machines, and
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training in the use of standard guidelines for manage-
ment of hyperbilirubinaemia. This intervention led to a
one-third reduction in the ET rate for outborn neonates
and a reduction by two-thirds in the ET rate for inborn
neonates in one hospital, and no change in the other; a
supplementary analysis, with a new post-intervention
period defined post hoc, showed both inborn NCUs
achieved a two-thirds reduction in ET after provision of
additional high intensity phototherapy machines.
An important lesson from the current pilot was that
provision of two LED machines was sufficient to make a
difference in a hospital with fewer than 400 annual ad-
missions for jaundice, but failed to have an impact in a
hospital with over 800 annual admissions for jaundice.
We hypothesise that this was because neonates were
being removed from LED phototherapy before the
completion of their treatment due to high demand
for machines. In line with the remedial action taken
in the current study, the provision of one LED ma-
chine per 150–200 annual admissions for jaundice
treatment is recommended. If this is not feasible, the
current data suggest that it is preferable to ensure
complete treatment on a subset of high risk neonates,
to prevent ET in that subset, rather than partial treat-
ment on multiple neonates, which risks no benefit in
terms of ET averted.
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